Akèy › Limfom Selil-T › Massachusetts
Etid klinik pou Limfom Selil-T nan Massachusetts
9 etid pou Limfom Selil-T ap chèche patisipan nan sit nan Massachusetts.
Vil nan Massachusetts
Tèks ofisyèl etid la (Anglè)
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT04803201Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
- Massachusetts General Hospital, Boston
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT06561048A Study of Ruxolitinib and Duvelisib in People With Lymphoma
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT05010005A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT06854653A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Massachusetts General Hospital, Boston
Ap rekriteFaz 1/2
Laj 18 ak plis · Tout sèks · Mizajou Aug 19, 2026 · NCT04104776Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
- Dana Farber Cancer Institute, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jun 11, 2026 · NCT05313243A Registry for People With T-cell Lymphoma
- Massachusetts General Hospital (Data Collection Only), Boston
- Dana Farber Cancer Institute (Data Collection Only), Boston
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou May 20, 2026 · NCT05978141MB-105 in Patients With CD5 Positive T-cell Lymphoma
- Massachusetts General Hospital, Boston
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Oct 3, 2025 · NCT06534060Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Dana-Farber Cancer Institute, Boston
Ap rekriteFaz 1
Laj 1 a 21 · Tout sèks · Mizajou Dec 6, 2024 · NCT05476770Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.